52 related articles for article (PubMed ID: 24981039)
1. Association between serum IgG concentrations and the incidence of infections in patients with chronic lymphocytic leukemia and secondary immunodeficiency under treatment with Privigen.
Otremba B; Haslbauer F; Reiser M; Weide R; Obermeier M; Pfründer D
Int J Clin Pharmacol Ther; 2024 Jun; 62(6):241-249. PubMed ID: 38577752
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Léger JM; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Mielke O; Tackenberg B; Shebl A; Bauhofer A; Zenker O; Merkies IS;
J Peripher Nerv Syst; 2013 Jun; 18(2):130-40. PubMed ID: 23781960
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.
Melamed IR; Gupta S; Stratford Bobbitt M; Hyland N; Moy JN
Clin Exp Immunol; 2016 May; 184(2):228-36. PubMed ID: 26696596
[TBL] [Abstract][Full Text] [Related]
5. Comparison of American and European practices in the management of patients with primary immunodeficiencies.
Hernandez-Trujillo HS; Chapel H; Lo Re V; Notarangelo LD; Gathmann B; Grimbacher B; Boyle JM; Hernandez-Trujillo VP; Scalchunes C; Boyle ML; Orange JS
Clin Exp Immunol; 2012 Jul; 169(1):57-69. PubMed ID: 22670779
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study.
Mahlaoui N; Fouyssac F; Mazingue F; Mallebranche C; Barthez-Toullec M; Denti L; Ruhier K; André-Bonnet MH; Marie-Cardine A; Aladjidi N; Stephan JL
Front Pediatr; 2023; 11():1260296. PubMed ID: 37849499
[TBL] [Abstract][Full Text] [Related]
7. Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis.
Dimou M; Speletas M; Milito C; Pyzik A; Huscher D; Kamieniak M; Pittrow D; Borte M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760493
[TBL] [Abstract][Full Text] [Related]
8. Privigen immune globulin intravenous (human), 10% liquid.
P T; 2011 Aug; 36(8 Section 2):2-31. PubMed ID: 21935292
[No Abstract] [Full Text] [Related]
9. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
11. Safety of L-proline as a stabilizer for immunoglobulin products.
Hagan JB; Wasserman RL; Baggish JS; Spycher MO; Berger M; Shashi V; Lohrmann E; Sullivan KE
Expert Rev Clin Immunol; 2012 Feb; 8(2):169-78. PubMed ID: 22288455
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
Dorsey MJ; Ho V; Mabudian M; Soler-Palacín P; Domínguez-Pinilla N; Rishi R; Rishi R; Wong D; Rojavin M; Hubsch A; Berger M
J Clin Immunol; 2014 Oct; 34(7):804-12. PubMed ID: 24981039
[TBL] [Abstract][Full Text] [Related]
13. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
[TBL] [Abstract][Full Text] [Related]
15. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
